Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- SMCI +12%, TRV +5.9%, STT +5.6%, JBHT +3.6%, ALLY +2.4%, MATX +1.3%, JBT +1.2%
Other news:
- MESA +65.6% (enters new agreements with United Airlines (UAL) for improved operating and financing terms and provides update on CRJ-900 asset sale program)
- SAVE +18.8% (Spirit Airlines and JetBlue (JBLU) are reviewing the Court's decision and evaluating next steps)
- VSTM +8.1% (FDA grants Fast Track designation for Avutometinib/Sotorasib treatment)
- MESO +8.1% (receives FDA's Rare Pediatric Disease Designation for Revascor)
- CHRS +7.5% (presents Phase 2 clinical data on Casdozokitug)
- SLM +3.3% (White House announces nearly $5 billion in additional student debt cancellation for 74000 borrowers)
- AVA +2% (files multi-year rate plan with the Washington)
- IBN +2% (provides CICI Securities delisting update)
- ED +1.8% (increases dividend)
- NVDA +1.8% (Meta (META) CEO Mark Zuckerberg posts on Instagram that company is purchasing AI products including 350k H100s (NVDA) by the end of this year -- and overall almost 600k H100s equivalents of compute power)
- WEN +1.2% (names former PEP exec as new CEO; reaffirms FY23 guidance)
- GOOG +1.1% (GOOG and SPOT joining NFLX by not launching applications for upcoming AAPL Vision Pro according to Bloomberg)
- AZN +1.1% (announces Voydeya granted first-ever regulatory approval in Japan for adults with PNH to be used in combination with C5 inhibitor therapy)
- SPOT +1% (GOOG and SPOT joining NFLX by not launching applications for upcoming AAPL Vision Pro according to Bloomberg)
Analyst comments:
- CCI +1.3% (upgraded to Market Perform from Underperform at BMO Capital Markets)
- DKNG +1.2% (upgraded to Buy from Hold at Stifel)